Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026

Vivani Medical, Inc.

2026-Q1 EPS reported -$0.08

Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).
Cash, equivalents and capital commitments of $28M expected to fund operations through first half of 2027.
Raised $9.7M in financing in Q1 2026, including $2.2M from a registered direct offering.
SLIM-1 Phase 1 trial of NPM-139 semaglutide implant to start mid-2026; top-line results by end of 2026.
Cortigent spin-off or IPO under consideration; S-1 amendment filed May 13, 2026.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.